News
Current position:Product Center > Antibodies > In Vivo MAb Antibodies > Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Product Info
Get A Quote

Cat. No:GM-88254MAB

Product:Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody


Cat. No. & Size
Get A Quote

GM-88254MAB-1mg / 1 mg

GM-88254MAB-5mg / 5 mg

GM-88254MAB-25mg / 5 mg * 5 vials

GM-88254MAB-50mg / 50 mg

GM-88254MAB-100mg / 50 mg * 2 vials



Description
Get A Quote

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

VEGF&PD1

Alternative Names

PD1: CD279

VEGF: VPF; MVCD1; L-VEGF

Source/Isotype

Monoclonal human IgG1 D265A, Kappa

Application

Flow cytometry; Block assay

Description

PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.

Formulation

20 mM Histidine, 150 mM NaCl, pH6.0



Data
Get A Quote

image.png

image.png

image.png

image.png


Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Current position:Product Center > -- > Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
classify
Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody
Product Info
Get A Quote

Cat. No:GM-88254MAB

Product:Anti-Mouse_PD1×VEGF hIgG1 Bispecific Antibody


Cat. No. & Size
Get A Quote

GM-88254MAB-1mg / 1 mg

GM-88254MAB-5mg / 5 mg

GM-88254MAB-25mg / 5 mg * 5 vials

GM-88254MAB-50mg / 50 mg

GM-88254MAB-100mg / 50 mg * 2 vials



Description
Get A Quote

Expression System

CHO

Aggregation

< 5% as determined by SEC-HPLC

Purity

> 95% as determined by SDS-PAGE

Endotoxin

< 1 EU/mg, determined by LAL gel clotting assay

Sterility

0.2 μm Filtered

Target

VEGF&PD1

Alternative Names

PD1: CD279

VEGF: VPF; MVCD1; L-VEGF

Source/Isotype

Monoclonal human IgG1 D265A, Kappa

Application

Flow cytometry; Block assay

Description

PD-1/VEGF Bispesific Antibody is a novel cancer immunotherapy drug that can target both PD-1 and VEGF. It blocks the interaction between PD-1 and PD-L1/PD-L2. The bispecific antibody can specifically bind to VEGFA and PD-1, selectively relieve the immune suppression caused by VEGFA and PD-1 in the body, and inhibit tumor-induced angiogenesis.

Formulation

20 mM Histidine, 150 mM NaCl, pH6.0



Data
Get A Quote

image.png

image.png

image.png

image.png


Message Consultation
If you have more questions, please fill in the relevant information,we'll respond as soon as possible to assist you!
Reset
Submit
You can also contact us on the Scientist and Science Exchange marketplaces.
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit